|
Gene |
Clone |
Species |
Stages |
Anatomy |
pax3.L
|
|
laevis
|
NF stage 12
|
neural crest
,
neural plate border
|
pax3.L
|
|
laevis
|
NF stage 16
|
hatching gland
,
neuroectoderm
,
neural crest
,
neural fold
,
neural plate border
|
pax3.L
|
|
laevis
|
NF stage 22
|
hatching gland
,
neuroectoderm
,
neural crest
,
neural plate
,
neural tube
,
[+]
|
pax3.L
|
|
laevis
|
NF stage 24
|
hatching gland
,
neuroectoderm
,
neural tube
|
|
|
Fig. 2.
Generation of Pax3-GFP transient transgenic embryos. (A) pax3 or CMV promoters fused to GFP were injected into Xenopus embryos as described to generate transient transgenic embryos. (B) GFP fluorescence was examined at neurula stage (stage 19). (C) CMV-GFP transient transgenic embryo, showing ubiquitous expression. (D) Pax3-GFP transient transgenic embryo showing expression restricted to the neural folds. (E, F) In situ hybridization (ISH) for comparison of endogenous Pax3 expression with GFP expression in Pax3-GFP transient transgenic embryos. (E) ISH for pax3 at the indicated stages. (F) ISH for GFP in Pax3-GFP embryos at the indicated stages. Note the similar expression of Pax3 and GFP. 92% of Pax3-GFP embryos exhibited expression in the neural folds (n= 210). |
|
|
|
Fig. 3.
Pax3-GFP responds to Wnt signaling. (A, C, E) ISH for endogenous Pax3 in wild type embryos at the indicated stages. (B, D, F) ISH for GFP in Pax3-GFP transient transgenic embryos at the indicated stages. Embryos were non-injected (Control) or injected with an inducible form of β-catenin (β-Cat-GR) and treated with DXM (in DMSO) to induce β-catenin, or DMSO alone. (G) Quantification of the percentage of embryos that showed expansion in Pax3/GFP expression. Note that activation of β-catenin leads to an equivalent increase of Pax3 and GFP expression. *** P<0.001. |